资料单张
CLIMARA
®
CMI
1
CONSUMER MEDICINE INFORMATION
CLIMARA
_oestradiol _
WARNING
The Women’s Health Initiative (WHI) trial examined the health
benefits and risks of combined
_oestrogen plus progestogen_ therapy (n=16,608)
and _oestrogen-alone_ therapy (n=10,739) in
postmenopausal women aged 50 to 79 years.
The _oestrogen plus progestogen_ arm of the WHI trial indicated an
increased risk of
_myocardial infarction (MI), stroke, invasive breast cancer, pulmonary
embolism and deep vein _
_thrombosis _in postmenopausal women receiving treatment with
combined conjugated equine
estrogens (CEE, 0.625 mg/day) and medroxyprogesterone acetate (MPA,
2.5 mg/day) for 5.2
years compared to those receiving placebo.
The _oestrogen-alone_ arm of the WHI trial indicated an increased
risk of_ stroke and deep vein _
_thrombosis _in hysterectomised women treated with CEE-alone (0.625
mg/day) for 6.8 years
compared to those receiving placebo.
Other doses of oral conjugated oestrogens with medroxyprogesterone
acetate, and other
combinations and dosage forms of oestrogens and progestogens were not
studied in the WHI
clinical trials and, in the absence of comparable data, these risks
should be assumed to be
similar.
Therefore, the following should be given serious consideration at the
time of prescribing:
•
Oestrogens with or without progestogens should not be prescribed for
primary or
secondary prevention of cardiovascular diseases.
•
Oestrogens with or without progestogens should be prescribed at the
lowest effective
dose for the approved indication.
•
Oestrogens with or without progestogens should be prescribed for the
shortest period
possible for the approved indication.
•
For the prevention of osteoporosis, oestrogen treatment should be
considered in light
of other available therapies.
CLIMARA
®
CMI
1_ _
CLIMARA
®
(CLIM·AR·RAH)
_oestra
阅读完整的文件
产品特点
Climara PI Feb2012
Page 1
PRODUCT INFORMATION
CLIMARA
®
WARNING
Oestrogens with or without progestogens should not be used for
the prevention of cardiovascular disease or
dementia.
The Women’s Health Initiative (WHI) study reported
increased risks of stroke and deep vein thrombosis in
postmenopausal women (50 to 79 years of age) during
6.8 years of treatment with conjugated oestrogens
(0.625 mg) relative to placebo (see CLINICAL TRIALS and
PRECAUTIONS).
The WHI study reported increased risks of myocardial infarction,
stroke, invasive breast cancer, pulmonary
emboli, and deep vein thrombosis in
postmenopausal women (50 to 79 years of age) during
5 years of
treatment with conjugated oestrogens (0.625 mg) combined
with medroxyprogesterone acetate (2.5 mg)
relative to placebo (see CLINICAL TRIALS and PRECAUTIONS).
The Women’s Health Initiative Memory Study (WHIMS),
a sub-study of WHI, reported increased risk of
developing probable dementia in
postmenopausal women 65 years of age
or older during 4 to 5.2 years of
treatment with conjugated oestrogens, with or
without medroxyprogesterone acetate, relative to placebo. It is
unknown whether this finding applies to younger
postmenopausal women (see CLINICAL TRIALS and
PRECAUTIONS).
Other doses of conjugated oestrogens and
medroxyprogesterone acetate, and other combinations and
dosage forms of oestrogens and progestogens were not studied in
the WHI clinical trials and, in the absence
of comparable data, these risks should be
assumed to be similar. Because of these
risks, oestrogens with or
without progestogens should be prescribed at the lowest effective
doses and for the shortest duration
consistent with treatment goals and risks for
the individual woman.
NAME OF THE MEDICINE
CLIMARA is a transdermal delivery system containing oestradiol as the
阅读完整的文件